Roy A. Whitfield SEC Filing

Roy A. Whitfield, a director at NEKTAR THERAPEUTICS, acquired 2,000 shares of Common Stock on September 23, 2026, with a transaction price of $0.00. This acquisition was made under a grant of restricted stock units (RSUs), which vest in full one year after the grant date. Following this transaction, Whitfield directly owns 16,417 shares of Common Stock. Additionally, Whitfield has indirect ownership of 3,434 shares through the Whitfield Family 2020 Trust and 1,334 shares through a Family Trust. The filing also reports the acquisition of a Stock Option for 4,000 shares of Common Stock on the same date, which vests over a one-year period starting September 23, 2026. All share amounts have been adjusted to reflect a 1-for-15 reverse stock split effected on June 8, 2025.